NetworkNewsBreaks

MondaySep 11, 2017 1:31 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on September 11, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MRNS 41.51% – News: Reports positive top-line data from CDKL5 trial ATOS 12.76% – News: Will host conference call on September 14 to discuss preliminary results from phase 1 study of Endoxifen NVFY 11.82% – News: Achieves record financial profit for the summer months of 2017 MNGA 12.33% – News: Provides operational update; August sales increase 57% YOY DMPI 10.17% – News: Initiates phase 2 clinical trial to explore safety and efficacy of VAL-083…

Continue Reading

MondaySep 11, 2017 1:11 pm

NetworkNewsBreaks – Tetra Bio-Pharma (TSX.V: TBP) (OTCQB: TBPMF) Accelerates its Cannabis-based Clinical Research Program in the Veterinary Market

Tetra Bio-Pharma (TSX.V: TBP) (OTCQB: TBPMF), a biopharmaceutical leader in cannabinoid-based drug discovery and development, is adding international expert Dr. Louis-Philippe de Lorimier, a board certified veterinary oncologist, to its clinical advisory board for the veterinary market. In a news release, Dr. Guy Chamberland, chief scientific officer of Tetra Bio-Pharma, said, "We are leveraging our current R&D work in humans to accelerate the development of the first cannabinoid-based drug for pets in the cancer-associated supportive therapy market, including pain. This market is underserved and patients and their owner are waiting for alternatives that are safer, more tolerable and more efficacious.”…

Continue Reading

MondaySep 11, 2017 12:19 pm

NetworkNewsBreaks – Terra Tech Corp. (TRTC) Files Provisional Patent Application for Cannabis-Infused Rolling Papers

Terra Tech Corp. (OTCQX: TRTC), a vertically integrated, cannabis-focused agriculture company, has filed a patent application with the U.S. Patent and Trademark Office for innovative cannabis-infused rolling papers. Expected to launch in 2018, the inventive rolling papers will be the latest addition to the company’s portfolio of IVXX™ branded premium cannabis products, which includes flowers, concentrates, custom-rolled joints and edibles. As with all its products, the rolling papers will be free of toxic pesticides, harmful molds and chemical residues, the company states. In the news release, Derek Peterson, CEO of Terra Tech, said, “Infusing rolling papers with cannabis can enhance…

Continue Reading

MondaySep 11, 2017 10:04 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Retains Biopsy, LLC to Provide Leadership in Growth and E-Commerce

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its retention of Biopsy, LLC, managed by bestselling author Chris J. Snook, to provide leadership in growth and e-commerce. Effective September 1, 2017, Biopsy, LLC will serve as the architect of the digital infrastructure and go-to-market strategy for ChineseInvestors.com, Inc. and its subsidiaries, reporting directly to the companies’ management teams. “ChineseInvestors.com, Inc. is fortunate to be able to contract with Biopsy, LLC as Chris' unique skill and experience will enhance the Company's ability to effectively emerge as a leader in the CBD Biotechnology Industry, while also strengthening and expanding the…

Continue Reading

MondaySep 11, 2017 9:10 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Linking THC to Decrease in Aβ40 Protein Production

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced compelling in vitro data compiled from genetically engineered cell lines showing that, at varying concentrations of THC, the production of Aβ40 protein decreases by as much as 50 percent over a 48-hour period. This is particularly noteworthy for patients with Alzheimer’s disease, as the condition often results in an imbalance of Aβ plaque that is believed to be toxic to nerve cells. This data, compiled by Dr. Chuanhai Cao, an IGC senior advisor and associate professor of pharmaceutical…

Continue Reading

FridaySep 08, 2017 12:14 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on September 8, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ONS 80.00% – News: Partners with GMS Tenshi Holdings Pte. Ltd for private placement of up to $25M of ONS Series A stock EGLT 6.11% – News: Presented data demonstrating potential of ARYMO ER for opioid abuse OPGN 5.60% – News: Presents data on new rapid gene test and antibiotic susceptibility prediction algorithms NTEC 4.58% – News: Will present at 19th Annual Rodman & Renshaw Global Investment Conference on September 12 GFN 3.00% –…

Continue Reading

FridaySep 08, 2017 12:10 pm

NetworkNewsBreaks – Achaogen, Inc. (NASDAQ: AKAO) Receives ‘Buy’ Rating at Mizuho Securities

Mizuho Securities USA LLC has initiated coverage and issued a ‘Buy’ rating and price target of $28 on shares of Achaogen, Inc.’s (NASDAQ: AKAO) stock. Achaogen has a broad pipeline of novel anti-bacterial drugs currently in development, including its lead candidate Plazomicin, which the analyst considers to be a value driver for the company. Following the positive results from the pivotal EPIC and CARE trials for treatment of complicated urinary tract infections (cUTIs) and Carbapenem Resistant Enterobacteriaceae (CRE), the company is preparing Plazomicin to file a New Drug Application (NDA) close to year-end. For more information, visit www.Achaogen.com About Achaogen…

Continue Reading

FridaySep 08, 2017 12:08 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on ViewRay, Inc. (NASDAQ: VRAY)

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $12 on shares of ViewRay, Inc.’s (NASDAQ: VRAY) stock. The company designs, manufactures and markets the MRIdian® radiation therapy system, which received CE-mark approval and 510(k) approval in February of this year. The analyst sees immense potential in the MRI-guided LINAC to disrupt current radiation oncology. The MRI-LINAC offers real-time imaging improving dosimetry and reduces the toxicity to patients, which makes for stiff competition for other companies that seem to have recently began to focus on real-time imaging. Additionally, the analyst believes that the company…

Continue Reading

FridaySep 08, 2017 12:05 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage on Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) with ‘Buy’ Rating

Mizuho Securities USA LLC has initiated coverage and issued a ‘Buy’ rating and price target of $32 on shares of Alder BioPharmaceuticals, Inc.’s (NASDAQ: ALDR) stock. Among other highlights, the analyst noted the company’s 'de-risked' asset, Eptinezumab, slated for an upcoming phase 3 PROMISE 2 read-out anticipated during the first half of 2018. The company has previously posted positive results from its first pivotal trial, PROMISE 1, which led the analyst to expect comparable results from PROMISE 2, as the studies' designs are similar. For more information, visit www.AlderBio.com About Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical…

Continue Reading

FridaySep 08, 2017 12:03 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on Zogenix, Inc. (NASDAQ: ZGNX)

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $28.00 on shares of Zogenix, Inc.’s (NASDAQ: ZGNX) stock after the company hit a new 52-week high on Wednesday. The company’s lead product candidate for the treatment of seizures associated with Dravet syndrome, ZX008, was noted by the analyst as having a strong efficacy. The analyst also cited clinical data that suggests ZX008 shows a superior long-term efficacy profile over its competitors with tolerable side effects. Upcoming catalysts for the company include phase 3 read-outs in the third quarter of 2017, and either the fourth…

Continue Reading